A cancer immunologist by training, Dr. Christopher Nirschl received his PhD from the Johns Hopkins School of Medicine in Immunology in 2015, and completed a postdoctoral fellowship at the Brigham and Women’s Hospital in association with Harvard Medical School. He has been studying the interactions between cancer and the immune system for over a decade, and is also one of the inventors of the anti-TIGIT antibody ASP8374/PTZ-201 which is currently in clinical trials. Currently, Dr. Nirschl is an Immunologist at Werewolf Therapeutics in Massachusetts, where he lives with his wife and two children. Be on the lookout for his book, "What the Heck Is A Clinical Trial?", out this coming winter!
@worldxppodcast Instagram - https://bit.ly/3eoBwyr@worldxppodcast Twitter - https://bit.ly/2Oa7Bzm Spotify - http://spoti.fi/3sZAUTGApple Podcasts - http://apple.co/30uGTnyGoogle Podcasts - http://bit.ly/3v8CF2UAnchor - http://bit.ly/3qGeaH7YouTube - http://bit.ly/3rxD
